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Background: Vitamin D displays immunomodulatory activities and has been proposed as a potential player in the
pathogenesis of rheumatoid arthritis (RA). A negative association between serum 25(OH) vitamin D levels and RA
activity was demonstrated but longitudinal studies investigating the role of vitamin D levels in predicting RA
activity and response to treatment are lacking. Therefore, this study was designed to test the hypothesis of an
association between serum 25(OH) vitamin D levels at RA diagnosis and disease activity evaluated by clinimetric,
laboratory and ultrasound (US) parameters and to detect the prevalence of remission and response to treatment
after 12 months follow-up.
Methods: This is a longitudinal, retrospective study on data obtained from thirty-seven patients with early RA
treatment-naïve. Serum inflammatory markers, auto-antibodies and 25(OH) vitamin D levels were obtained at
baseline. Hypovitaminosis D was diagnosed for 25(OH) vitamin D levels < 20 ng/ml. Tender joint count (TJCs),
swollen joint count (SJCs), Visual Analog Scales (VAS), Disease Activity Score (DAS) 28 score were assessed at baseline
and 12 months after diagnosis. Joints synovitis and power-Doppler were evaluated at baseline and 12 months later.
Results: At baseline mean 25(OH) vitamin D levels were 24.4 ± 11.9 ng/ml; 35% of study subjects had hypovitaminosis
D which strongly associated with higher RA activity and lower prevalence of remission and response to treatment (all
p-values < 0.001). The percentage of patients not presenting a reduction of the US synovitis score after 12 months from
diagnosis was significantly higher among patients with hypovitaminosis D than in those with normal serum 25(OH)
vitamin D at baseline.
Conclusions: In patients with early RA and basal hypovitaminosis D after 12 months follow-up reduction of disease
activity and percentage of remission and response to treatment were significantly lower than those observed in
patients with normal vitamin D levels. These results provide further support to the immunomodulatory action
of vitamin D in RA and suggest a role of basal vitamin D status in the prediction of disease evolution. Vitamin D
measurement and possibly vitamin D supplementation should be considered an additional option in the management
of early RA patients.
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Rheumatoid arthritis (RA) is a chronic autoimmune disease
characterized by joint involvement and systemic features,
leading to a progressive disability and early death [1]. It
affects approximately 1% of the population, with higher
prevalence in women. Although its aetiology is still un-
known, it has been theorized that in genetically susceptible
individuals environmental factors trigger an autoimmune
response resulting in synovial hypertrophy and chronic joint
inflammation and destruction associated with potential
extra-articular manifestations [2]. It has been demonstrated
that the active form of vitamin D, the 1,25-dihydroxyvitamin
D (1,25(OH)2D), besides its role in calcium and bone
homeostasis, acts as a modulator of immune cells such as
macrophages, dendritic cells and activated T cells, express-
ing its specific vitamin D receptor (VDR) [3,4]. Further-
more, 1,25(OH)2D displays an anti-inflammatory role also
acting on Th17 cells, contributing to the maintenance of
the immunological homeostasis [5-7]. In murine models
1,25(OH)2D was able to prevent the onset and progression
of arthritis and VDR deficient mice (VDR−/−) showed a
more aggressive disease [8,9]. Some epidemiological stud-
ies showed a higher prevalence of vitamin D deficiency
among patients affected by RA compared with healthy
population [10-15], whereas other investigations did not
confirm these findings [16,17]. Furthermore, a recent meta-
analysis demonstrated that low vitamin D intake is associ-
ated with high risk of RA and that a negative association
exists between serum vitamin D levels and RA activity
[18]. Likewise, evidence about the relationship between
hypovitaminosis D and early RA are contrasting [19-21].
Interestingly, an intervention trial conducted in a popula-
tion of patients with early RA and disease-modifying anti-
rheumatic drugs (DMARDs)-naïve showed that trimestral
calcitriol supplementation along with triple DMARDs ther-
apy resulted in significant higher pain relief compared with
treatment with triple DMARDs plus calcium [14].
At the best of our knowledge, longitudinal studies inves-
tigating the role of vitamin D levels at RA diagnosis on the
prediction of disease’s activity, remission and response to
treatment are missing. Therefore, aims of this study were
to test the hypothesis of an association between serum 25
(OH) vitamin D levels at the diagnosis of RA and: 1- the
disease’s activity evaluated by clinimetric, laboratory and
ultrasound (US) parameters, 2- the prevalence of remis-
sion and response to treatment in a population of patients
affected by early RA naïve for DMARDs treatment, after
12 months of follow-up.
Methods
Study population
This is a longitudinal observational retrospective study
with a 12 months follow-up. Data from seventy-six con-
secutive patients referring to the Early Arthritis Clinic,Rheumatology Unit, Sapienza University of Rome, for
recently onset RA between 2010 and 2012 were initially
obtained. Among them, we enrolled subjects which
fulfilled the following inclusion criteria: age between 30
and 65 years, subjects meeting the American College of
Rheumatology/European League Against Rheumatism
(ACR/EULAR) criteria for RA diagnosis [22], mean disease
duration ≤ 24 weeks, BMI 16–25 kg/m2, conscious accept-
ance of written informed consent. The exclusion criteria
were: treatment with vitamin D and/or calcium supple-
mentation or drugs affecting the bone and mineral metab-
olism, multivitamin supplementation, oral contraceptives,
parathyroid hormone, L-tyroxine, diuretics, DMARDs,
anti-epilepsies and steroids; intestinal malabsorption; dis-
eases associated with hypercalcaemia (lymphoma, sarcoid-
osis, tuberculosis infection, primary hyperparathyroidism);
acute/chronic kidney failure; acute/chronic hepatic fail-
ure; type 1 and type 2 diabetes mellitus; metabolic syn-
drome; history of drugs and/or alcohol abuse. Among the
initial seventy-six patients, thirty-seven subjects were
considered eligible for the study: fifteen patients were
excluded for treatment with drugs affecting the bone and
mineral metabolism, eight for multivitamin supplementa-
tion, one for oral contraceptives, three for treatment with
steroids, one for intestinal malabsorption, two for chronic
kidney failure, five for diabetes mellitus, three for meta-
bolic syndrome and one refused to participate.
Study population underwent 12 months follow-up (mean±
SD: 54 ± 3 weeks) during which they were treated with
low doses of corticosteroids (Prednisone < 10 mg/day) and
methotrexate (7.5-15 mg/week) and attended to quarterly
recall visits for clinical evaluation.
Laboratory tests
For each patient, we collected and analyzed data at base-
line (disease onset) and after 12-months follow-up on
medical history, physical examination and blood immune-
inflammatory parameters, such as: erythrocyte sedimentation
rate (ESR) (normal values: ≤15 mm/h in men and ≤20 mm/h
in female), C-reactive protein (CRP) level (normal
values: <3 mg/L), using standard laboratory methods
and to detect IgM-Rhematoid Factor (RF) by nephelometric
method (N latex FR, Bering, CV < 4%) and anti-citrullinated
protein antibodies (ACPA) by immune-enzymatic method
(ImmunoCap, Phadia, <5%). A titre of IgM-RF >15 IU/ml
was considered positive, the cut-off point for ACPA posi-
tivity was > 12 IU/ml, according to the manufacturer’s
instructions.
In order to evaluate vitamin D status in our population
at the diagnosis of RA, serum levels of 25(OH) vitamin
D (ng/ml), the most stable circulating form of this mol-
ecule were also measured [23,24]. In order to minimize
the impact of seasonality on circulating vitamin D con-
centrations, all participants underwent fasting blood
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ing autumn-winter period. Vitamin D was measured by
immunochemiluminescent method (LIAISON, DiaSorin,
CV < 5%) on sera frozen immediately after separation and
stored at −25°C for few days.Clinical assessment
Clinimetric assessment, routinely used in clinical prac-
tice and Clinical Trials to evaluate disease activity and
response to treatment, was performed by a rheumatolo-
gist experienced in clinimetric evaluation and blinded to
laboratory data. At baseline and 12 months of follow up
we collected data on: the number of tender and swollen
joints on the basis of the 28-joint count and 44-joint
count, Ritchie index (a graded assessment of 26 joint
regions), visual analogue scale (VAS 0–100 mm) for
pain and patient’s disease activity, examinator’s global
disease activity assessment (EGA), patient global health
assessment (GH) and 28-joints Disease Activity Score
(DAS28) [25].
At 12 months follow-up, EULAR response was calcu-
lated from the DAS28 scores. Study population was divided
in three EULAR response groups: no response, moderate
response or good response. To be a good responder, a pa-
tient had to show an improvement of at least 1.2 units and
achieve an absolute score of < 3.2. Non-responders had to
show an improvement of < 0.6, or > 0.6 and ≤ 1.2, and have
a final DAS28 score of > 5.1. Moderate responses fell in-
between these criteria [26].Musculoskeletal ultrasonography
US evaluation was performed both at baseline and after
a 12-months follow-up. A systematic multiplanar grey-
scale and powerDoppler (pD) examination of 17 joints
[wrist, metacarpophalangeal (MCP) joints, proximal in-
terphalangeal (PIP) joints, knee and metatarsophalangeal
(MTP) joints bilaterally] was performed according to
standard EULAR guidelines, by MyLab70 XVision Gold
(Esaote, Italy) machine equipped with a multifrequency
linear probe (6–18 MHz); powerDoppler PFR (peak
frequency ratio) was 750 Hz, Doppler frequency was
7.5 MHz. Synovial effusion (SE), synovial hypertrophy
(SH) and bone erosions were assessed according to the
Outcome Measures in Rheumatoid Arthritis Clinical Trial
(OMERACT) definitions [27]. US-detected elementary
lesions (SE, SH and pD signal) were scored according
to a semiquantitative scale based on the severity of
the US modifications (0 = normal; 1 = mild; 2 = moder-
ate; 3 = severe). The total synovitis score was obtained
from the sum of the all US modifications identified in all
the joints. Bone erosions were assessed with a semiquanti-
tative score as follows: grade 0 = no erosion, grade 1 = 1
erosion, grade 2 = 2 erosions, grade 3 ≥ 3 erosions.Statistics
SPSS version 17 statistical package was used to perform the
analyses. Non-parametric Mann–Whitney test for mean
comparison between two independent groups and Wilcoxon
test for mean comparison between two related groups
were used. The χ-squared test was used to compare the
rate of responders to treatment at 12 months follow-up
(moderate + good response vs non response) among pa-
tients with and without basal hypovitaminosis D. Bivariate
correlation analyses were performed by Spearman’s coeffi-
cient calculation. Study population was divided in two
subgroups according to vitamin D status considering
serum 25(OH) vitamin D < 20 ng/ml as a cut-off for insuf-
ficient vitamin D levels [28,29]. At the best of our know-
ledge, clinical remission and response to treatment by
DAS28 after a 12 months follow-up in relation to vitamin
D status at RA onset have never been studied before.
Therefore, in order to confirm the statistical power of this
study, we performed a post-hoc sample size calculation
considering a prevalence of remission in the subgroup
with normal vitamin D status of 68% and of 16% in pa-
tients with hypovitaminosis D; thus, we obtained that
eleven patients per subgroup were enough to reach the
statistical significance with a power of 80% (α error = 0.05,
β error = 0.20). For all the above, a p-value < 0.05 was con-
sidered statistically significant. Study protocol was reviewed
and approved by the Ethics Committee of Policlinico
Umberto I, Sapienza University of Rome and conducted
in conformance with the Helsinki Declaration. Writ-
ten consent was obtained from all patients before the
study.
Results
The study included 37 early RA patients. These were
mostly female (6 M/31 F) with a mean (SD) age of 47 ±
12 years and median disease duration (SD) of 24 ±
13 weeks. Clinical, biochemical and US characteristics of
study population at baseline and after 12 months from
diagnosis are shown in Table 1.
Baseline characteristics
Study population had mean serum 25(OH) vitamin D
concentrations of 24.4 ± 11.9 ng/ml; notably, 35% of our
sample was affected by hypovitaminosis D at the time of
RA diagnosis. Serum 25(OH) vitamin levels were not as-
sociated with basal DAS28. In order to characterize our
patients according to vitamin D status, we stratified the
study sample in two subgroups in relation to the vitamin
D balance: patients affected by hypovitaminosis D (25(OH)
vitamin D ≤ 20 ng/ml) and with sufficient vitamin D levels
(25(OH) vitamin D > 20 ng/ml).
Baseline clinimetric, biochemical and US characteristics
did not differ significantly between the two subpopula-
tions although there was a trend in increased prevalence
Table 1 Clinimetric, laboratory and ultrasound characteristics of study population at baseline and after 12 months
follow-up
Patients (N = 37) Baseline 12 months follow-up P-value
ESR (mm/h), mean ± SD 31 ± 21 13.9 ± 11 0.0001^
CRP (g/L), mean ± SD 13.6 ± 16 5.81 ± 4.71 0.003^
RF positivity, number (%) 31 (83) 31 (83) -
APCA positivity, number (%) 30 (81) 30 (8) -
Morning stiffness (minutes), mean ± SD 62 ± 48 20.8 ± 23 0.0001^
Ritchie index, mean ± SD 10 ± 8.2 2.5 ± 2.9 0.00001^
VAS pain (mm), mean ± SD 63 ± 24 31.9 ± 32 0.002^
VAS disease patient (mm), mean ± SD 58 ± 23 31 ± 27 0.0001^
EGA (mm), mean ± SD 54 ± 20 24.3 ± 20 0.0001^
Number of tender joints (0–44), median (range) 12 (0–35) 2 (0–19) 00001^
Number of swollen joints (0–44), median (range) 5 (0–22) 3 (0–21) 0.0001^
Number of tender joints (0–28), median (range) 8 (0–24) 4 (0–30) 0.0001^
Number of swollen joints (0–28), median (range) 5 (0-20 5 (0–32) 0.0001^
DAS 28 score, mean ± SD 5.18 ± 1 2.77 ± 1.14 0.0001^
Ultrasound Total Synovitis score, mean ± SD 25.7 ± 21.7 8.31 ± 6.2 0.0008^
Ultrasound Total power Doppler score, mean ± SD 3.3 ± 5.9 0.65 ± 1.22 0.005^
Ultrasound Total Erosion score, mean ± SD 1.34 ± 2.7 10.31 ± 9.8 ns^
Patients ≥1 erosion, number (%) 12 (32%) 18 (48%) ns*
X-Ray Erosion, +ve, number (%)/% 6 (16%) -
Results are shown as mean ± SD, median(min-max) or number(percentage) of patients, as appropriated. ^Wilcoxon test applied, *chi-squared test applied. P-value <0.05
are considered significant. ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, Rheumatoid Factor; ACPA, anti-citrullinated protein antibodies; VAS, visual
analogue scale; EGA, examinator’s global disease activity assessment; DAS28, 28-joint disease activity score.
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in patients affected by hypovitaminosis D compared
with subjects with normal 25(OH) vitamin D levels.
Furthermore, US synovitis joint score was significantly
associated with DAS28 (Spearman’s coefficient = 0.5,
p = 0.003).
12 months follow-up characteristics
After 12 months from RA diagnosis in the overall popu-
lation there was a significant reduction of disease’s activity,
as expressed by ESR, serum CRP levels, TJCs, SJCs and
DAS28, and US synovitis and p-D score (all p-values <
0.001), as expected (Table 1).
Among the whole study population, individuals with
hypovitaminosis D at baseline had significantly higher
disease activity at the 12 months follow-up evaluated by
clinimetric index, compared with patients with sufficient
25(OH) vitamin D levels. Furthermore, ESR, CRP and
US inflammatory and US bone erosion scores were in-
creased in presence of hypovitaminosis D although these
differences did not reach the statistical significance.
Clinimetric, laboratory and US characteristics of study
population according to vitamin D status at baseline and
12 months follow-up are shown in Table 2.Response to RA treatment and clinical remission at
12 months from diagnosis
After 12 months follow-up all participants were in treatment
with low doses of corticosteroids (Prednisone < 10 mg/day)
and methotrexate (7.5-15 mg/week). Among our study
population 91.7% patients were responders to RA treat-
ment (2.7% good and 89% moderate responders) accord-
ing to the EULAR response criteria. Disease remission
(DAS28 < 2.6) was achieved by 48% of patients. The per-
centage of responders was significantly lower in the
subgroup of patients with hypovitaminosis D compared to
subjects with normal 25(OH) vitamin D levels at baseline
(25(OH) vitamin D < 20 ng/ml: 75% responders (0% good,
75% moderate response) vs 25(OH) vitamin D > 20 ng/ml:
100% responders (4% good, 96% moderate response, p <
0.001).
Similarly, the percentage of patients in remission was
significantly reduced in hypovitaminosis D subgroup com-
pared with the normal 25(OH) vitamin D one as showed
by clinimetric index DAS28 (16% vs 68%, p < 0.001). The
same results were obtained also using other clinimetric in-
dexes such as DAS44, CDAI and SDAI (not shown) thus
reinforcing the evidence for the association between hypo-
vitaminosis D and disease activity/response to treatment.
Table 2 Characteristics of study population at baseline and after 12 months follow-up according to vitamin D status at
the time of RA diagnosis
Parameters Baseline 12 months follow up
25(OH)D <20 ng/ml
(N = 13)
25(OH)D >20 ng/ml
(N = 24)
P-value 25(OH)D <20 ng/ml
(N = 13)
25(OH)D >20 ng/ml
(N = 24)
P-value
Age, mean ± SD 51.3 ± 13.1 46.0 ± 11.2 ns^ - - -
Sex, M/F 2/11 3/22 ns* - - -
BMI (Kg/m2), mean ± SD 25.5 ± 5.2 25.5 ± 4.2 ns^ - - -
Vitamin D (ng/ml), mean ± SD 12.4 ± 3.4 30.4 ± 9.9 0.0001^ - - -
Disease Duration (weeks), mean ± SD 21.6 ± 12.8 23.8 ± 18.1 ns^ - - -
Morning stiffness (minutes), mean ± SD 56.6 ± 49.4 83.6 ± 102.2 ns^ 38.3 ± 27.2 12.1 ± 15.8 0.002^
ESR (mm/h), mean ± SD 25.9 ± 13.1 35.5 ± 25.4 ns^ 15 ± 10 13.4 ± 12.9 ns^
CRP (g/L), mean ± SD 8.2 ± 8.2 16.4 ± 19.3 ns^ 5.1 ± 4.2 4.1 ± 4.7 ns^
RF positivity, number (%) 11 (85%) 20 (83%) ns * 9 (69%) 13 (54%) 0.002*
APCA positivity, number (%) 11 (85%) 19 (79%) ns* 10 (77%) 18 (75%) ns*
Ritchie Index, mean ± SD 10.5 ± 8.45 9.71 ± 8.32 ns^ 4.25 ± 3.52 1.62 ± 2.28 0.004^
VAS pain (mm), mean ± SD 64.2 ± 19.9 60.8 ± 27 ns^ 61.4 ± 31.2 20.1 ± 25.1 0.001^
VAS disease patient (mm), mean ± SD 58 ± 23.6 57.8 ± 24.4 ns^ 48.7 ± 27.3 21.6 ± 22.3 0.004^
EGA (mm), mean ± SD 52.7 ± 26.2 54.8 ± 18.3 ns^ 36 ± 20.5 17.6 ± 18.5 0.01^
Global Health, mean ± SD 48.6 ± 22.3 63.9 ± 17.3 ns^ 35 ± 16.2 17.3 ± 11.8 0.03^
Number of tender joints (0–44),
median (range)
11.5 (2–35) 11.5 (0–33) ns^ 6 (1–19) 1 (0–13) 0.002^
Number of swollen joints (0–44),
median (range)
5 (1–22) 5.5 (0–13) ns^ 1.5 (0–9) 0 (0–8) 0.02^
Number of tender joints (0–28),
median (range)
7 (2–24) 7.5 (0–23) ns^ 3.5 (1–11) 0 (0–4) 0.001^
Number of swollen joints (0–28),
median (range)
3.5 (1–20) 5 (0–13) ns^ 1.5 (0–8) 0 (0–8) 0.01^
DAS 28 score, mean ± SD 5.1 ± 0.7 5.2 ± 1.2 ns^ 3.6 ± 1.03 2.3 ± 0.9 0.001^
Remission (DAS28 < 2.6), number (%) - - - 2 (16) 16 (68) 0.001
Low disease activity (DAS28 2.6-3.2),
number (%)
0 (0) 1 (4.2) 2 (15) 4 (16)
Moderate disease activity
(DAS 28 3.2-5.1), number (%)
10 (77) 11 (45.8) 8 (62) 3 (12)
High disease activity (DAS28 > 5.6),
number (%)
4 (23) 12 (50) 1 (8) 1 (4)
Good responders, number (%) - - - 0 (0) 1 (4)
Moderate responders, number (%) - - - 10 (75) 23 (96)
No responders, number (%) - - - 3 (25) 0 (0)
Ultrasound Total Synovitis score,
mean ± SD
26.5 ± 31.3 25.4 ± 17.4 ns^ 14.3 ± 15.6 8.1 ± 6.2 ns ^
Ultrasound Total power Doppler score,
mean ± SD
4.6 ± 8.9 2.7 ± 4.2 ns^ 0.83 ± 1.32 0.57 ± 1.26 ns^
Ultrasound Total Erosion score,
mean ± SD
1.2 ± 2.3 1.4 ± 3 ns^ 11.8 ± 6.4 9.6 ± 11.2 ns^
Results are shown as mean ± SD or number (percentage) of patients, as appropriated. ^Mann–Whitney test applied, *chi-squared test applied. P-value <0.05 are
considered significant. ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, Rheumatoid Factor; ACPA, anti-citrullinated protein antibodies; VAS, visual
analogue scale; EGA, examinator’s global disease activity assessment; DAS28, 28-joint disease activity score.
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sponse to RA treatment and the clinical remission after
12-month from RA diagnosis were associated with baselinevitamin D status (Spearman’s coefficient 0.45, p = 0.006;
Spearman’s coefficient 0.55, p < 0.001, respectively) and did
not correlate with age, gender, BMI, CRP, ESV, DAS28,
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Moreover, the multivariate logistic analysis demonstrated
that baseline vitamin D status independently predicted the
response to RA treatment after adjusting for age, gender
and all possible confounders (p < 0.006, see also Additional
file 1: Table S1). Notably, in our study population, baseline
hypovitaminosis D was associated with an over 3-fold in-
crease (OR: 3.5; 95% C.I.: 1.3-9.5, χ2 test applied) in the risk
of no response to RA treatment after 12 months follow-up.
The existence of a worse response to treatment in
patients with hypovitaminosis D compared to those with
normal 25(OH) vitamin D levels at RA onset was also
demonstrated by US. Although individual US scores
underwent changes that were not significantly different
between the two groups, when calculating the difference
between US total synovitis scores at baseline and 12-
month follow-up, a significant difference was observed
between score variation in patients with hypovitaminosis
D and the one in patients with normal 25(OH) vitamin
D (Variation: −7.1 ± 15.3 vs −20.4 ± 12.9, respectively;
p = 0.01).
Discussion
In this study we demonstrated that the occurrence of
hypovitaminosis D in early RA is predictive of a reduced
response to treatment and higher disease activity as eval-
uated after 12 months follow-up. Low vitamin D levels
were found in 35% of study population and vitamin D
levels were not associated with basal RA activity. So far,
conflicting evidence exists regarding the association
between vitamin D deficiency and RA susceptibility and
prognosis. Although an overall high prevalence of vita-
min D deficiency in RA has been largely described, some
studies found comparable serum 25(OH) vitamin D con-
centrations between patients with RA and healthy con-
trols [16,17]. Gheita TA et al. recently found reduced
25(OH) vitamin D levels in RA patients compared with
controls and that, among RA patients, vitamin D was sig-
nificantly lower in subjects with fibromyalgia syndrome in
addition to RA [15]. Other studies evaluated prospectively
the risk of RA in relation to vitamin D intake, but again
the results are conflicting [18,30,31].
So far, evidence of a relationship between vitamin D
serum levels and disease activity in early RA patients is
limited to a report on a negative association [21,32] be-
tween serum vitamin D at baseline and HAQ score after
12 months follow-up, but neither RA activity nor re-
sponse to treatment were investigated. Cross-sectional
studies on the association between baseline 25(OH) vita-
min D levels and disease’s activity in early RA patients
did not obtain univocal results [19-21].
In our study, as expected, we observed an overall
significant reduction of RA activity, evaluated by clini-
metric, laboratory and US parameters, after 12 monthsof treatment. In fact, the outcome of the disease has im-
proved considerably in recent years with the availability
of effective therapies and the recognition that early
intensive treatment strategies result in better outcomes.
Interestingly, at the end of follow-up we found that pa-
tients with hypovitaminosis D exhibited significantly
higher disease activity and reduced percentage of remis-
sion and lower response to treatment compared with
those with sufficient 25(OH) vitamin D levels at baseline,
suggesting a role of vitamin D in disease progression
and prognosis. Over the past decade the immunomodula-
tory role of vitamin D has become more defined. Experi-
mental data show that vitamin D metabolites play a
modulatory role on T cell proliferation and dendritic cell
function via VDRs expression on these cells [33]. Notably,
the expression of VDRs was also demonstrated on acti-
vated lymphocytes, synoviocytes, macrophages, and chon-
drocytes in the course of RA [33]. In murine models of
collagen-induced arthritis, vitamin D supplementation
prevents both the onset and progression of arthritis
[8]. Further support for a role of VDR/vitamin D system
in the pathogenesis of RA is also provided by epidemio-
logical studies showing the existence of an association
between VDR Fok1polymorphism and RA susceptibil-
ity [34,35].
One limitation of the present study is the small num-
ber of patients; another limit is the short duration
follow-up, as 12 months may not be enough to ascertain
whether vitamin D status at baseline has long term effects
on RA activity, particularly referring to structural damage.
Moreover, as no previous data are available on clinical
remission/response to treatment after a 12 month follow-
up in relation to vitamin D status at RA onset, we just
performed a post-hoc sample size calculation, confirming
the statistical power of our findings.
Our study however, has several strengths: it is the first
longitudinal study investigating the role of vitamin D
status in predicting RA activity and response to treat-
ment in early and DMARDs-naïve RA and evaluates for
the first time the prognostic value of vitamin D status
on US parameters in RA, such as synovitis, p-D and
bone erosion US scores.
Conclusions
In conclusion, our study demonstrates that hypovitami-
nosis D at RA onset is predictive of a reduced response
to treatment in early RA after 12 months of follow-up.
These results provide further support to the immuno-
modulatory action of vitamin D in inflammatory arthritis
and suggest a potential prognostic role of vitamin D sta-
tus at diagnosis in RA evolution. Serum vitamin D meas-
urement and possibly vitamin D supplementation should
be considered an additional option in the management
of early RA patients.
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